BridgeBio Pharma logo

BridgeBio PharmaNASDAQ: BBIO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

27 June 2019

Next earnings report:

21 February 2025

Last dividends:

N/A

Next dividends:

N/A
$4.35 B
-43%vs. 3y high
88%vs. sector
-vs. 3y high
-vs. sector
-378%vs. 3y high
6%vs. sector
-98%vs. 3y high
85%vs. sector

Price

after hours | Fri, 22 Nov 2024 21:05:58 GMT
$23.02$0.00(0.00%)

Dividend

No data over the past 3 years
$2.73 M$43.39 M
$2.73 M-$162.04 M

Analysts recommendations

Institutional Ownership

BBIO Latest News

BridgeBio: Next Chapter Begins After Attruby Approval
seekingalpha.com24 November 2024 Sentiment: -

BridgeBio announced the FDA approval of Attruby (acoramidis) for the treatment of patients with ATTR-CM. The label looks clean and it includes all the relevant clinical data. Attruby's approval also triggers a $500 million milestone payment to BridgeBio under the royalty-backed deal it signed earlier this year and removes a regulatory and funding overhang on the stock.

US FDA approves BridgeBio's drug for rare heart condition
reuters.com22 November 2024 Sentiment: POSITIVE

The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said on Friday, making it the first new treatment in a market dominated by Pfizer's blockbuster Vyndaqel.

Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
globenewswire.com22 November 2024 Sentiment: POSITIVE

- Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been shown to preserve the native function of TTR as a transport protein of thyroxine and vitamin A and to demonstrate benefit on cardiovascular outcomes

BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
globenewswire.com18 November 2024 Sentiment: POSITIVE

- In Cohort 5 of PROPEL 2, daily oral treatment of infigratinib at 0.25mg/kg resulted in statistically significant and sustained increases in annualized height velocity (AHV), with a mean change from baseline of +2.50cm/year at Month 18 (P=0.001)

BridgeBio Announces Publication of Case Study Exploring Portfolio Theory's Impact on Biomedical Innovation in The Journal of Portfolio Management
globenewswire.com05 November 2024 Sentiment: POSITIVE

- Case study co-authored by members of BridgeBio senior management and BridgeBio co-founder and MIT professor, Andrew W. Lo, Ph.D.

3 Top Stocks That Could Still Rocket Higher in 2024
fool.com04 October 2024 Sentiment: POSITIVE

Upcoming Food and Drug Administration decisions could push these stocks through the roof.

BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
globenewswire.com03 October 2024 Sentiment: POSITIVE

PALO ALTO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced today that outcomes data through 42 months from the ongoing long-term open-label extension of ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a featured science oral presentation at the American Heart Association (AHA) Scientific Sessions, taking place in Chicago, Illinois on November 16 – 18, 2024. In addition to the presentation, BridgeBio was selected to share three posters in moderated poster sessions on ATTR-CM.

BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events
globenewswire.com27 September 2024 Sentiment: POSITIVE

- Acoramidis treatment led to a highly significant reduction in all-cause mortality (ACM) and recurrent cardiovascular-related hospitalizations (CVH) at Month 30 compared with placebo

3 Best High-Growth Mid-Cap Stocks to Buy in September 2024
247wallst.com18 September 2024 Sentiment: POSITIVE

Investors are optimistic that small- and mid-cap stocks will rally this year after a tough 2023, as attention shifts from the AI-focused Magnificent Seven.

BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
globenewswire.com17 September 2024 Sentiment: POSITIVE

- Breakthrough Therapy Designation was granted based on preliminary clinical evidence from the PROPEL 2 clinical trial, meeting the FDA's requirement of potentially demonstrating substantial improvement in efficacy over available therapies on clinically significant endpoint(s)

What type of business is BridgeBio Pharma?

BridgeBio Pharma, Inc. is a pharmaceutical company engaged in research and development of various drugs for genetic diseases. The company was founded in 2015, with its headquarters located in Palo Alto, California. BridgeBio Pharma's portfolio includes about 20 development programs for various products at different stages of development. The company's main candidates are: BBP-265, an oral low-molecular-weight transthyretin (TTR) intended for the treatment of transthyretin amyloidosis. Infigratinib, an oral selective FGFR1-3 tyrosine kinase inhibitor for the treatment of FGFR-driven cancer and achondroplasia. BBP-631, a preclinical gene transfer candidate product for the treatment of congenital adrenal hyperplasia (CAH) caused by 21OHD. BBP-454, a preclinical research program focused on new approaches to inhibiting KRAS for cancer treatment.

What sector is BridgeBio Pharma in?

BridgeBio Pharma is in the Healthcare sector

What industry is BridgeBio Pharma in?

BridgeBio Pharma is in the Biotechnology industry

What country is BridgeBio Pharma from?

BridgeBio Pharma is headquartered in United States

When did BridgeBio Pharma go public?

BridgeBio Pharma initial public offering (IPO) was on 27 June 2019

What is BridgeBio Pharma website?

https://bridgebio.com

Is BridgeBio Pharma in the S&P 500?

No, BridgeBio Pharma is not included in the S&P 500 index

Is BridgeBio Pharma in the NASDAQ 100?

No, BridgeBio Pharma is not included in the NASDAQ 100 index

Is BridgeBio Pharma in the Dow Jones?

No, BridgeBio Pharma is not included in the Dow Jones index

When was BridgeBio Pharma the previous earnings report?

No data

When does BridgeBio Pharma earnings report?

The next expected earnings date for BridgeBio Pharma is 21 February 2025